Institution
Rambam Health Care Campus
Healthcare•Haifa, Israel•
About: Rambam Health Care Campus is a healthcare organization based out in Haifa, Israel. It is known for research contribution in the topics: Population & Cancer. The organization has 2498 authors who have published 3715 publications receiving 104362 citations. The organization is also known as: Rambam Hospital & Bet ha-ḥolim ha-memshalti Rambam.
Topics: Population, Cancer, Medicine, Transplantation, Breast cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A brief review of major milestones in medical imaging from its inception to date is provided, with a few considerations regarding future directions in this important field.
Abstract: Today medical imaging is an essential component of the entire health-care continuum, from wellness and screening, to early diagnosis, treatment selection, and follow-up. Patient triage in both acute care and chronic disease, imaging-guided interventions, and optimization of treatment planning are now integrated into routine clinical practice in all subspecialties. This paper provides a brief review of major milestones in medical imaging from its inception to date, with a few considerations regarding future directions in this important field.
60 citations
••
TL;DR: Changes in vascular FDG activity and CT calcifications can be assessed by repeat PET/CT, and FDG-avid foci may represent a dynamic process, transient inflammation, whereasCT calcifications may indicate stable atherosclerosis.
59 citations
••
TL;DR: Pembrolizumab as mentioned in this paper demonstrated clinically meaningful and durable antitumor activity with a manageable safety profile in recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC).
59 citations
••
GeneDx1, Harvard University2, Boston Children's Hospital3, Johns Hopkins University4, Kennedy Krieger Institute5, Baylor College of Medicine6, Rambam Health Care Campus7, Johns Hopkins University School of Medicine8, University of California, San Francisco9, Queen's University10, Arnold Palmer Hospital for Children11, University of Texas at Austin12, Brigham and Women's Hospital13, LSU Health Sciences Center New Orleans14, New York University15, University Health Network16, University of Toronto17, Stanford University18, Cleveland Clinic19
TL;DR: Functional assays revealed that these MORC2 variants result in hyperactivation of epigenetic silencing by the HUSH complex, supporting their pathogenicity and expanding the spectrum of genetic disorders resulting from pathogenic variants in MORC1.
Abstract: MORC2 encodes an ATPase that plays a role in chromatin remodeling, DNA repair, and transcriptional regulation. Heterozygous variants in MORC2 have been reported in individuals with autosomal-dominant Charcot-Marie-Tooth disease type 2Z and spinal muscular atrophy, and the onset of symptoms ranges from infancy to the second decade of life. Here, we present a cohort of 20 individuals referred for exome sequencing who harbor pathogenic variants in the ATPase module of MORC2. Individuals presented with a similar phenotype consisting of developmental delay, intellectual disability, growth retardation, microcephaly, and variable craniofacial dysmorphism. Weakness, hyporeflexia, and electrophysiologic abnormalities suggestive of neuropathy were frequently observed but were not the predominant feature. Five of 18 individuals for whom brain imaging was available had lesions reminiscent of those observed in Leigh syndrome, and five of six individuals who had dilated eye exams had retinal pigmentary abnormalities. Functional assays revealed that these MORC2 variants result in hyperactivation of epigenetic silencing by the HUSH complex, supporting their pathogenicity. The described set of morphological, growth, developmental, and neurological findings and medical concerns expands the spectrum of genetic disorders resulting from pathogenic variants in MORC2.
59 citations
••
TL;DR: The first indication of the impact of cannabis consumption during immune checkpoint inhibitors immunotherapy cancer treatment is provided and it is shown that the levels of endogenous serum eCB and eCB-like lipids are affected by immunotherapy and may potentially constitute monitoring targets to cancer immunotherapy treatment, which currently has poor clinical markers for predicting patient response rates.
Abstract: Cannabis or its derivatives are widely used by patients with cancer to help with cancer symptoms and treatment side effects. However, cannabis has potent immunomodulatory properties. To determine if cannabis consumption during immunotherapy affects therapy outcomes, we conducted a prospective observatory study including 102 (68 immunotherapy and 34 immunotherapy plus cannabis) consecutive patients with advanced cancers who initiated immunotherapy. Cannabis consumption correlated with a significant decrease in time to tumor progression and overall survival. On the other hand, the use of cannabis reduced therapy-related immune-related adverse events. We also tested the possibility that cannabis may affect the immune system or the tumor microenvironment through the alteration of the endocannabinoid system. We analyzed a panel of serum endocannabinoids (eCBs) and eCB-like lipids, measuring their levels before and after immunotherapy in both groups. Levels of serum eCBs and eCB-like lipids, before immunotherapy, showed no significant differences between cannabis users to nonusers. Nevertheless, the levels of four eCB and eCB-like compounds were associated with patients’ overall survival time. Collectively, cannabis consumption has considerable immunomodulatory effects, and its use among cancer patients needs to be carefully considered due to its potential effects on the immune system, especially during treatment with immunotherapy.
59 citations
Authors
Showing all 2516 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jorge E. Cortes | 163 | 2784 | 124154 |
James A. Russell | 124 | 1024 | 87929 |
Barry M. Brenner | 121 | 540 | 65006 |
Razelle Kurzrock | 118 | 1121 | 56594 |
Alan R. Saltiel | 99 | 336 | 49325 |
Michael Aviram | 94 | 479 | 31141 |
Jacob M. Rowe | 75 | 328 | 20043 |
Richard G. Wunderink | 72 | 368 | 26892 |
Doron Aronson | 64 | 261 | 13357 |
Nathan McDannold | 64 | 208 | 16293 |
Jacob I. Sznajder | 61 | 273 | 12201 |
Joseph Itskovitz-Eldor | 60 | 212 | 38298 |
Yehuda Chowers | 60 | 211 | 14526 |
Raanan Shamir | 60 | 379 | 19927 |
David Tanne | 60 | 264 | 41513 |